Fig. 5

Trends in hCG changes and corresponding treatment regimens in four patients. A Patient A (IV: 14) was treated with the EMA-CO regimen, and hCG levels decreased to normal and remained stable. B Patient B (IV: 19) changed chemotherapy regimens successively to FAVE, paclitaxel + oxaliplatin + gemcitabine, TEP, BEP, MBE, EP-EMA, and pembrolizumab due to unsatisfactory hCG levels decreases. C Patient C changed chemotherapy regimens successively to FAVE and TEP due to recurrent elevated hCG levels. D Patient D changed chemotherapy regimens successively to EP-EMA, PEB, and FAEV due to unsatisfactory hCG level decreases